86
Participants
Start Date
January 31, 2015
Primary Completion Date
October 7, 2019
Study Completion Date
July 8, 2024
FEC100
"3 cycles of FEC 100 administered IV q3w~* 5-Fluorouracil (5-FU) 500 mg/m²~* Epirubicin 100 mg/m²~* Cyclophosphamide 500 mg/m²"
Docetaxel
TOP2A amplified : DOCETAXEL 75 mg/m² IV escalating at 100 mg/m² IV as tolerated q3w TOP2A not amplified : DOCETAXEL 75 mg/m² IV
Trastuzumab
Trastuzumab 8 mg/kg loading dose administered intravenously (IV) followed by 6 mg/kg IV q3w in subsequent cycles.
Pertuzumab
Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.
Carboplatin
CARBOPLATIN AUC 6 IV q3w
Institut de Cancerologie de L'Ouest - Site Paul Papin, Angers
Centre Hospitalier Regional Universitaire de Brest - Hôpital Morvan, Brest
Centre Francois Baclesse, Caen
Centre Jean Perrin, Clermont-Ferrand
Chu de Grenoble - Hopital Michallon, Grenoble
Chu de Limoges - Hôpital Dupuytren, Limoges
Centre Leon Berard, Lyon
Institut Regional Du Cancer Montpellier Val D'Aurelle, Montpellier
Institut de Cancerologie de L'Ouest - Site Rene Gauducheau, Saint-Herblain
Hopital D'Instructions Des Armees, Saint-Mandé
Centre Paul Strauss, Strasbourg
Institut de Cancerologie de Lorraine Alexis Vautrin, Vandœuvre-lès-Nancy
UNICANCER
OTHER